Authors' recommendations: Hepatocellular carcinoma (HCC) is primary cancer of the liver that accounts for more than 80% of all liver cancer types. Although HCC is uncommon in the United States, there are more than 1 million new cases diagnosed globally each year. HCC is an aggressive tumor that is one of the most common causes of cancer death worldwide. The overall 5-year survival rate for liver cancer is 15%. Signs and symptoms in the early stages of HCC are uncommon. Appropriate treatment for HCC depends upon the stage of disease. Only about 5% of patients are eligible for tumor resection, which is indicated in cases with solitary tumors that are confined to the liver and normal or well-preserved liver function. Patients with localized or locally advanced, unresectable cancer may be treated with liver transplantation. Most patients present with intermediate or advanced stage disease that is not amenable to curative treatments, such as liver transplantation. Local palliative therapies include percutaneous radiofrequency ablation, bland transarterial embolization (TAE), transarterial chemoembolization (TACE), drug-eluting bead TACE (DEB-TACE), radioembolization, or other forms of ablation.

Project Status: Completed

Year Published: 2013

URL for published report: The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=15770

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: 2013 Winifred S. Hayes, Inc